Scholars@Duke
Mustafa Khasraw

Scholarly Works - Conferences

Oncolytic HSV-1 Encoding IL-12 and Anti-PD-1 Reprograms CNS Immunity: Open-Label Study of MVR-C5252 for Safety, Tolerability, and Efficacy (PuMP) 2259418

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionTo overcome immunosuppression in glioblastoma (GBM), we evaluated MVR-C5252, an HSV-1 expressing interleuki ... Full text Cite

Spatial and vascular determinants of tumor-infiltrating lymphocyte expansion in glioblastoma 2260218

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionAdoptive transfer of tumor-infiltrating lymphocytes (TILs) has shown promise in solid tumors but remains li ... Full text Cite

Spatial Transcriptomics Reveals Immune Remodeling in Recurrent Oligodendroglioma 2259684

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionOligodendrogliomas frequently recur despite standard therapy, but how the immune microenvironment evolves d ... Full text Cite

A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination 2257077

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionImmunotherapy has yet to show efficacy in glioblastoma (GBM). To enhance immune priming, the ETAPA phase 1 ... Full text Cite

Comparing Systemic, Localized, and Focused Ultrasound-Mediated Delivery of Evolocumab (α-PCSK9) in a Murine Model of Glioblastoma 2303312

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionKey challenges in treating glioblastoma are the immunosuppressive tumor microenvironment and the blood-brai ... Full text Cite

Endogenous Retrovirus Neoantigen Enables Personalized Cancer Vaccine in glioblastoma, IDH-wildtype 2259068

Conference The Journal of Immunology · August 1, 2026 AbstractIntroductionGlioblastoma (GBM) remains refractory to immunotherapy due to low mutational burden and limited neoantigens ... Full text Cite

Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.

Conference Journal of Clinical Oncology · June 1, 2026 TPS2102Background: Glioblastoma (GBM) remains a fatal malignancy despite multimodalit ... Full text Cite

Abstract 2496: In silico screening of therapeutics candidates targeting minimal residual disease in glioblastoma

Conference Cancer Research · May 15, 2026 AbstractBackground:Glioblastoma recurrence is inevitable despite aggressive surgical resection of contrast enhancing (CE) tumor ... Full text Cite

Abstract 6477: Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale:Immunotherapy has yet to yield benefit in glioblastoma (GBM), in part due to inadequate T-cell p ... Full text Cite

Abstract 7769: IL-12/anti-PD-1 armored oncolytic HSV-1 reprograms CNS immunity: Integrated longitudinal immune, genomic, and metabolic CSF profiling in the MVR-C5252 PuMP Trial

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale:Glioblastoma (GBM) remains refractory to immunotherapy and exhibits low basal IL-12 and IFN-γ le ... Full text Cite

Abstract 4956: Spatial and vascular microenvironmental features predict tumor-infiltrating lymphocyte expansion in glioblastoma

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale:Adoptive transfer of tumor-infiltrating lymphocytes (TILs) has demonstrated meaningful clinical ... Full text Cite

Abstract 6212: Spatial immune and vascular remodeling defines recurrence in oligodendroglioma

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale:Oligodendrogliomas recur after therapy but how spatial immune architecture changes during recurr ... Full text Cite

Abstract 6975: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale: Glioblastoma is refractory to immunotherapy because of low mutational burden and paucity of canonical neoan ... Full text Cite

Abstract 1293: A multimodal AI framework integrating spatial omics and radiomics for recurrence prediction in glioblastoma.

Conference Cancer Research · April 3, 2026 AbstractIntroduction/Rationale: Glioblastoma (GBM) has a dismal prognosis, yet times to recurrence vary substantially. We integrated multim ... Full text Cite

Abstract 4256: Long-read RNA sequencing and immunopeptidomics reveal transcriptomic aberrationneoantigens as targets for T cell immunotherapy in diffuse glioma

Conference Cancer Research · April 3, 2026 AbstractBackground:Diffuse Glioma (DG) exhibits low tumor mutational burden and limited responsiveness to immunotherapy, sugges ... Full text Cite

Abstract 6841: Contrasting immune-tumor (predator-prey) dynamics in glioblastoma and melanoma to explain divergent responses to checkpoint blockade.

Conference Cancer Research · April 3, 2026 AbstractBackground:Glioblastoma is largely resistant to immune checkpoint blockade (ICB), unlike melanoma where patients routin ... Full text Cite

TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDLerapolturev is a modified, non-pathogenic version of the Sabin™ type 1 poliovirus vaccine that infects myelo ... Full text Cite

INNV-39. Response to next interventions after treatment with off-label ivosidenib in patients with mutant IDH low grade glioma

Conference Neuro-Oncology · November 11, 2025 AbstractThe introduction of mutant IDH inhibitors (mIDHi) has transformed the treatment landscape for patients with low-grade gliomas (LGG). However, optimal strategies for tumor control following progres ... Full text Cite

QOL-07. Vitamin B6 supplementation for levetiracetam-associated mood changes in patients with brain tumor-related epilepsy

Conference Neuro-Oncology · November 11, 2025 AbstractSeizures are a common and debilitating complication of primary brain tumors. Nearly 75% of low-grade and 25% of high-grade glioma patients experience seizures. Levetiracetam (LEV) is frequently us ... Full text Cite

TIP-06. A global, open-label, randomized Phase 3 trial evaluating niraparib compared to standard temozolomide therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Conference Neuro-Oncology · November 11, 2025 AbstractGlioblastoma (GBM) carries a uniformly poor prognosis. Lack of methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, present in around 60% of GBM tumors, is associated with li ... Full text Cite

BIOM-79. TARGETING FGFR ALTERATIONS IN GLIOMAS: A SINGLE-INSTITUTION CASE SERIES

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDFibroblast growth factor receptor (FGFR) alterations are a potentially actionable target in various cancers, ... Full text Cite

OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDThe P30-EPS vaccine is a novel multi-epitope peptide immunotherapy targeting class I HLA-A2 epitopes of tumor-associ ... Full text Cite

KS03.4.A SPATIAL MULTI-OMIC PROFILING REVEALS DETERMINANTS OF TIL EXPANDABILITY IN HIGH-GRADE GLIOMAS

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDTumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in melanoma and is emerging as a promising mod ... Full text Cite

KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDOncolytic viruses represent a promising immunotherapeutic strategy by combining direct tumor lysis with local immune ... Full text Cite

P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDGlioblastoma (GBM) is a universally deadly disease with dismal prognosis. The O6-methylguanine methyltransferase (MG ... Full text Cite

A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.

Conference Journal of Clinical Oncology · June 2025 TPS2096Background: Glioblastoma (GBM) is associated with dismal prognosis and poor quality of life. In approximately 60% of t ... Full text Cite

Abstract CT057: Evaluation of tumor associated P30-peptide antigen (ETAPA): Safety and immunogenicity in a phase 1b trial in glioblastoma

Conference Cancer Research · April 25, 2025 AbstractWe developed a novel peptide-based vaccine, P30-EPS, which combines the universal class II-binding P30 epitope derived from tetanus toxoid with HLA-A2:01 class I peptides from tumor-associated antige ... Full text Cite

Abstract CT056: A phase 1 study of intratumoral HSV1 co-expressing IL-12 and PD1 blocking antibody (MVR-C5252) in recurrent high-grade glioma

Conference Cancer Research · April 25, 2025 AbstractBackground:Recurrent glioblastomas (GBM) and other high-grade gliomas (HGG) have poor outcomes. Oncolytic viruses (OVs) offer ... Full text Cite

BIOM-66. GENOME-WIDE DNA METHYLATION PATTERNS IN PERIPHERAL BLOOD OF PATIENTS WITH GLIOBLASTOMA ENROLLED ON THE PHASE II VERTU TRIAL

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDFor patients with glioblastoma, the identification of a non-invasive biomarker for longitudinal molecular profiling ... Full text Cite

CTIM-01. OUTCOMES AND IMMUNE RESPONSES AFTER PEPTIDE VACCINATION TARGETING HUMAN CYTOMEGALOVIRUS ANTIGEN PP65 IN CHILDREN AND YOUNG ADULTS WITH RECURRENT HIGH-GRADE GLIOMA AND MEDULLOBLASTOMA: RESULTS OF A PHASE 1 TRIAL

Conference Neuro-Oncology · November 11, 2024 AbstractINTRODUCTIONThe human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblast ... Full text Cite

IMMU-18. IL-7 MEDIATED UPREGULATION OF VLA-4 INCREASES ACCUMULATION OF ADOPTIVELY TRANSFERRED T LYMPHOCYTES IN MURINE GLIOMA

Conference Neuro-Oncology · November 11, 2024 AbstractWe have previously described the development of a novel brain bi-specific T cell engager (BRiTE) targeting EGFRvIII in Glioma. Despite BRiTEs impressive potency, efficacy in solid tumors is dependent ... Full text Cite

IMMU-52. A NOVEL MHC-INDEPENDENT MECHANISM FOR CD8+ T CELL KILLING

Conference Neuro-Oncology · November 11, 2024 AbstractThe long-accepted paradigm for both cellular and antitumor immunity relies upon tumor cell kill by CD8+ T cells recognizing cognate antigens presented in the context of target cell major histocompati ... Full text Cite

TMIC-45. CYTOMEGALOVIRUS PP65 ANTIGEN EXPRESSION FOLLOWING PP65-SPECIFIC DENDRITIC CELL VACCINATION IN MATCHED PRIMARY AND RECURRENT GLIOBLASTOMA SPECIMENS

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDHuman cytomegalovirus (HCMV) expression in glioblastoma (GBM) has been corroborated by multiple independent laborato ... Full text Cite

INNV-07. IVOSIDENIB AND BEVACIZUMAB IN HEAVILY PRETREATED PATIENTS WITH IDH1 MUTANT GLIOMAS

Conference Neuro-Oncology · November 11, 2024 AbstractIsocitrate dehydrogenase 1 (IDH1) inhibitors are transforming the treatment of patients with non-enhancing IDH1 mutant gliomas that have only undergone surgical resection. Questions remain on the uti ... Full text Cite

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 11, 2024 AbstractGBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common con ... Full text Cite

INNV-31. THE USE OF IVOSIDENIB IN PATIENTS WITH ENHANCING IDH1 MUTANT GLIOMAS

Conference Neuro-Oncology · November 11, 2024 AbstractIvosidenib offers a novel targeted therapy for non-enhancing IDH1 mutated gliomas following initial resection. Potential effects of IDH inhibitors on enhancing disease in clinical settings are not we ... Full text Cite

CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDGBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, internat ... Full text Cite

INNV-37. REAL-WORLD OUTCOMES AMONG HIGH GRADE IDH1-MUTANT GLIOMA PATIENTS TREATED WITH AN IDH INHIBITOR

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDIsocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH- ... Full text Cite

NIMG-77. MRI PHENOMENON OF PUNCTATE ENHANCING LESIONS IN PATIENTS TREATED WITH IDH INHIBITORS

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDMagnetic Resonance Imaging (MRI) response assessment is essential in isocitrate dehydrogenase (IDH)-mutant gliomas a ... Full text Cite

P18.37.B REPEATED CONVECTION-ENHANCED DELIVERY (CED) INFUSION OF A POLIO/RHINOVIRUS RECOMBINANT (LERAPOLTUREV; LERA) IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS, FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS OF LERA (LERA-CPLI)

Conference Neuro-Oncology · October 17, 2024 AbstractBACKGROUNDPhase 1 and 2 clinical trials of a single intratumoral injection of LERA (previously PVSRIPO) via CED into enhancing ... Full text Cite

P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · October 17, 2024 AbstractBACKGROUNDGBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, internat ... Full text Cite

OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Conference Neuro-Oncology · October 17, 2024 AbstractBACKGROUNDGBM AGILE (NCT03970447;https://www.gcaresearch.org/research/gbm-agile) is a phase 3 Bayesian adaptive platform trial ... Full text Cite

Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)

Conference Breast · April 1, 2024 Introduction, A decade ago, stereotactic radiosurgery (SRS) without whole brain radiotherapy (WBRT) was emerging as preferred treatment for oligometastatic brain metastases. Studies of cavity SRS after neurosurgery were underway. Data specific to metastati ... Full text Cite

NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).

Conference Journal of Clinical Oncology · January 20, 2024 589Background: Neuroendocrine carcinomas (NEC) are rare and aggressive cancers. There ... Full text Cite

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

Characterization of industry relationships in oncology.

Conference Cancer · September 15, 2023 BACKGROUND: Collaborative relationships between academic oncology and industry (pharmaceutical, biotechnology, "omic," and medical device companies) are essential for therapeutic development in oncology; however, limited research on engagement in and perce ... Full text Open Access Link to item Cite

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · September 8, 2023 AbstractBACKGROUNDGBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, internat ... Full text Cite

Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Conference Cancer Research · April 14, 2023 AbstractBackground: GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform tria ... Full text Cite

Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma (GBM), the most common primary malignant brain tumor in adults, is an incurable disease that has an inevitable tendency to recur following standard of care surgery, radiotherapy, and tem ... Full text Cite

Abstract 3193: Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma is the most prevalent primary brain malignancy, with a median survival of less than 21 months despite treatment with surgery, radiation, and chemotherapy. Significant intra-tumoral heter ... Full text Cite

Abstract 4061: Systemic autologous lymphocyte transfer can enhance tumor-infiltrating lymphocyte infiltration in glioblastoma and license co-stimulatory immunotherapy

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma is an immunologically ‘cold’ malignancy where few tumor infiltrating lymphocytes (TILs) are present. We sought to overcome this by ‘seeding’ the tumor with TILs via administration of aut ... Full text Cite

NCOG-43. A RETROSPECTIVE ANALYSIS OF THE IMPACT OF THE COVID-19 INFECTION ON NEURO-ONCOLOGY CARE AND PATIENT OUTCOMES: A TWO-SITE STUDY

Conference NEURO-ONCOLOGY · November 14, 2022 BACKGROUND COVID-19 radically changed neuro-oncology care. In this retrospective study, we examine the impact of COVID-19 infection on neuro-oncological care and clinical outcomes in two geographically separate populations. METHODS Descriptive statistics ... Full text Link to item Cite

P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma

Conference Neuro-Oncology · September 5, 2022 AbstractBackgroundGBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, internat ... Full text Cite

Characterization of industry relationships in oncology.

Conference · June 2, 2022 Abstract 11025 Background: Collaborative relationships between academic oncology and the pharmaceutical industry are essential for therapeutic development in oncology. Despite this, formal training and mentorship in developing productive industry collabora ... Full text Link to item Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

CTIM-24. NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA

Conference NEURO-ONCOLOGY · 2022 Abstract BACKGROUND Nivolumab is a PD-1 inhibitor with known safety profile. An increase in mutations as we age is well documented in glioblastoma and other cancers. Higher mutational load is associated with increased response to nivolumab in extracranial ... Full text Link to item Cite

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ... Full text Open Access Link to item Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference Neuro-Oncology · November 12, 2021 AbstractIsocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for t ... Full text Open Access Link to item Cite

INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThe use of telemedicine increased during the COVID-19 pandemic. However, the impact on patient satisfaction in the ... Full text Open Access Cite

BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDPVSRIPO is a live-attenuated recombinant rhino:poliovirus that mediates antitumor efficacy by engaging antitumor imm ... Full text Cite

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.

Conference Neuro Oncol · October 1, 2021 BACKGROUND: Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant po ... Full text Link to item Cite

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · June 1, 2021 AbstractIntroductionThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Link to item Cite

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

Conference Journal of Clinical Oncology · May 20, 2021 1091 Background: Tumor mutational burden (TMB) has emerged as an imperfect biomarker of immune checkpoint inhibition (ICI) outcomes in solid tumors. Despite the approval for pembrolizumab in all TMB-high (TMB-H) solid tumors, the ... Full text Cite

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2074 Background: GBM AGILE, Glioblastoma Adaptive, Global, Innovative Learning Environment, is an international, multi-arm, seamless phase 2/3 response adaptive randomization platform trial designed to evaluate multiple therap ... Full text Cite

A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

Conference Journal of Clinical Oncology · May 20, 2021 2585 Background: CDX-527 is a bispecific antibody (BsAb) targeting PD-L1 and CD27 that is designed to block immune checkpoint PD-L1/PD-1 interactions while providing immune costimulation through CD27 signaling. CD27 is a key immu ... Full text Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference NEURO-ONCOLOGY · 2021 Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for the gliomagenesis associated with these tumors and the pro ... Full text Link to item Cite

RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 9, 2020 AbstractDeveloping new therapies for patients with glioblastoma (GBM) requires focused interaction between industry, academia, nonprofits, patient advocacy, and health authorities, and novel approaches to cl ... Full text Cite

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Open Access Link to item Cite

Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts

Conference Cancer Research · February 15, 2020 AbstractBackground: Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has shown antitumor activity and a manageable safety profile in several tumor types. Talazoparib, an orally available PARP inhibitor ... Full text Cite

CTIM-21PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference NEURO-ONCOLOGY · 2020 Abstract INTRODUCTION The cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not in healthy brain. The objective of this Phase I trial (NCT03299309) was to assess the safety and feasibility of a novel ... Full text Link to item Cite

A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2019 2011 Background: TMZ offers minimal benefit in uMGMT GBM pts. V is synergistic with both RT and TMZ in preclinical models, safe when combined with either RT or TMZ clinically, but the triplet (V+RT+TMZ) is poorly tolerated. This ... Full text Cite

Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2019 2042 Background: The VERTU trial (ANZCTR #ACTRN12615000407594) compared Arm A (standard of care) = RT (60Gy/30 fractions) + TMZ (75mg/m2 daily) followed by TMZ (150–200mg/m2 D1–5) every 2 ... Full text Cite

AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.

Conference Journal of Clinical Oncology · February 1, 2018 TPS548 Background: Neuroendocrine carcinomas (NEC WHO grade 3) are rare and aggressive cancers. There are no randomised trials to date to establish standard therapy for advanced gastrointestinal (GI) NECs. Extrapolating from smal ... Full text Cite

Evaluating the Causes of Screen Failures in a Medical Oncology Clinical Trial Unit

Conference ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY · August 1, 2017 Link to item Cite

Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.

Conference Journal of Clinical Oncology · May 20, 2017 2062 Background: Recurrence in patients with glioblastoma (GBM) is inevitable, even in patients with O-6-Methylguanine-DNA Methyl Transferase ( MGMT) methylation. We identified increased expression of the inflammatory cytokine, M ... Full text Cite

The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.

Conference Journal of Clinical Oncology · February 1, 2017 380 Background: Sunitinib was approved by the FDA in 2011 for treatment of progressive, well-differentiated, advanced pancreatic neuroendocrine tumors (pNETs) based on a pivotal phase III study (NCT00428597) that showed a signifi ... Full text Cite

Abstract A12: Genomically unstable glioblastoma are sensitive to Parp inhibition

Conference Cancer Research · December 1, 2015 AbstractBackground: The development of effective targeted drugs for the treatment of glioblastoma (GBM) represents a major unmet need. Veliparib (ABT-888; Abbvie) inhibits both PARP1 and PARP2 (poly[ADP-ribo ... Full text Cite

SYMPTOM BURDEN OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET)

Conference Asia-Pacific Journal of Clinical Oncology · November 1, 2015 Link to item Cite

Mutational analysis of matched initial and recurrent TP53 WT primary GBM.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Abstract 3777: Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

Conference Cancer Research · October 1, 2014 AbstractIntroduction: The survival trends for glioblastoma (GBM) patients have remained largely static, reflecting lack of improvement in the therapeutic options for patients. Less than 5% of newly diagnosed ... Full text Cite

A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

A RETROSPECTIVE STUDY OF WOMEN WITH LATE PRESENTATIONS OF BREAST CANCER

Conference ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY · January 1, 2014 Link to item Cite

Patterns of care study of adult medulloblastoma.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

A survey of suspected familial breast cancer in Iraqi Kurdish women.

Conference Journal of Clinical Oncology · May 20, 2011 Full text Cite

ABSENCE OF EVIDENCE IS NO EVIDENCE OF ABSENCE

Conference NEURO-ONCOLOGY · October 1, 2008 Link to item Cite

Chemotherapy in the elderly

Conference Cancer Forum · March 1, 2008 The number of elderly patients with malignancy is growing and is likely to have a major impact on resources, quality of care, health economics and treatment options. Decisions regarding treatment options with chemotherapy are limited by the scarcity of dat ... Cite